Skip to main content
. 2012 Apr 24;7(4):e34422. doi: 10.1371/journal.pone.0034422

Table 2. Tp53 mutation and HPV DNA detection in skin lesions, perilesions and non-lesional control samples from subjects with and without SCC.

SCC subjects Control subjects P1 (les vs. peri) P2 (les vs. sun) P3 (peri vs. sun)
Lesional tissue (n = 55) Perilesion tissue (n = 55) Non-lesional sun-exposed tissue (n = 41) Non-lesional sun-protected tissue (n = 41)
Tp53 Mutations
 Any 18 (33%) 9 (16%)* 1 (2%)** 2 (5%) 0.03 <0.001 0.04
 Single 14 (25%) 8 (15%) 1 (2%) 0 (0%)
 Multiple 4 (7%) 1 (2%) 0 (0%) 2 (5%)
Non-synonymous coding mutations
 Any 17 (31%) 8 (15%)* 0 (0%)** 2 (5%) 0.03 <0.001 0.01
 Single 14 (25%) 7 (13%) 0 (0%) 1 (2%)
 Multiple 3 (5%) 1 (2%) 0 (0%) 1 (2%)
UV-damage C→T or CC→TT transition mutations
 Any 13 (24%) 7 (13%) 0 (0%)** 2 (5%) 0.11 <0.001 0.02
 Single 12 (22%) 6 (11%) 0 (0%) 1 (2%)
 Multiple 1 (2%) 1 (2%) 0 (0%) 1 (2%)
“Hotspot” Mutations ^
 Any 11 (20%) 4 (7%) 0 (0%)** 0 (0%) 0.05 0.002 0.13
 Single 10 (18%) 4 (7%) 0 (0%) 0 (0%)
 Multiple 1 (2%) 0 (0%) 0 (0%) 0 (0%)
HPV DNA 35/53 (66%) 29/53 (55%) 24/40 (60%) 21/41 (51%) 0.13 0.55 0.61
Beta 2 HPV Species 4/20 (20%) 4/20 (20%) 17/40 (43%) 14/41 (34%) 1.00 0.15 0.15
*

p-value<0.05 for cases compared to perilesions (McNemar’s Test).

**

p-value<0.05 for cases compared to sun-exposed controls (Chi-Square test).

^

Hotspots include Arg248Trp, Arg196Stop, and His179Stop.